Type 2 diabetes mellitus
Conditions
Interventions
The participants administrating 10 mg/day of empagliflozin or 5 mg/day of linagliptin are followed by empagliflozin/linagliptin combination tablet administration orally.
Sponsors
Kurume University School of Medicine Division of Endocrinology and Metabolism, Department of Internal Medicine
KURUME Medical Study Group of Internal Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with glycated haemoglobin (HbA1c) levels higher than 7.0% (National Glycohemoglobin Standardization Program, NGSP) [52 mmol/mol (International Federation of Clinical Chemistry and Laboratory Medicine, IFCC)], and medicated stable with linagliptin or empagliflozin for at least 3 months were included.
Exclusion criteria
Exclusion criteria: Patients with urinary tract infection such as pyelonephritis or with impaired renal function (eGFR [estimated Glomerular filtration rate] less than 30 ml/min/1.73 m2) were excluded
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes of grip strength | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes of body weight, HbA1c,blood glucose, blood pressure, circumstance length,GDS15 score,evaluation of psychosomatic activities in IPAQ-SF | — |
Countries
Japan
Contacts
Public ContactAyako Nagayama
Kurume University School of Medicine Division of Endocrinology and Metabolism, Department of Internal Medicine
Outcome results
None listed